CY1110026T1 - Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων - Google Patents

Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων

Info

Publication number
CY1110026T1
CY1110026T1 CY20101100403T CY101100403T CY1110026T1 CY 1110026 T1 CY1110026 T1 CY 1110026T1 CY 20101100403 T CY20101100403 T CY 20101100403T CY 101100403 T CY101100403 T CY 101100403T CY 1110026 T1 CY1110026 T1 CY 1110026T1
Authority
CY
Cyprus
Prior art keywords
methods
piperazine
benzisoxazole compounds
benzisoxazole
compounds
Prior art date
Application number
CY20101100403T
Other languages
Greek (el)
English (en)
Inventor
James F White
Daniel Coughlin
Dale M Edgar
Michael Solomon
David G Hangauer
Kazumi Shiosaki
Original Assignee
Hypnion, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion, Inc. filed Critical Hypnion, Inc.
Publication of CY1110026T1 publication Critical patent/CY1110026T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20101100403T 2005-04-26 2010-05-07 Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων CY1110026T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67520205P 2005-04-26 2005-04-26
EP06751667A EP1877390B1 (en) 2005-04-26 2006-04-26 Benzisoxazole piperazine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1110026T1 true CY1110026T1 (el) 2015-01-14

Family

ID=36754209

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100403T CY1110026T1 (el) 2005-04-26 2010-05-07 Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων

Country Status (15)

Country Link
US (3) US7494998B2 (https=)
EP (2) EP1877405B1 (https=)
JP (2) JP5049267B2 (https=)
CN (1) CN101208314B (https=)
AT (2) ATE459621T1 (https=)
AU (1) AU2006239302B2 (https=)
CA (2) CA2606473C (https=)
CY (1) CY1110026T1 (https=)
DE (2) DE602006013115D1 (https=)
DK (1) DK1877390T3 (https=)
ES (2) ES2340066T3 (https=)
MX (1) MX2007013352A (https=)
PL (1) PL1877390T3 (https=)
PT (1) PT1877390E (https=)
WO (1) WO2006116614A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
AU2006239302B2 (en) * 2005-04-26 2011-07-07 Hypnion, Inc. Benzisoxazole piperazine compounds and methods of use thereof
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
SG171681A1 (en) 2006-05-18 2011-06-29 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
CA2646076C (en) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
CN104069567A (zh) * 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2136863A2 (en) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009126830A2 (en) * 2008-04-09 2009-10-15 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA2741731A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
AU2009312474B2 (en) 2008-11-07 2014-12-04 Insuline Medical Ltd. Device and method for drug delivery
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8565107B2 (en) 2010-09-24 2013-10-22 Hand Held Products, Inc. Terminal configurable for use within an unknown regulatory domain
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
DK4299135T3 (da) 2019-06-18 2025-09-08 Pfizer Benzisoxazol-sulfonamid-derivater
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331541A (en) * 1965-06-07 1967-07-18 Bell & Howell Co Sprocketless projector
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
FR2654104B1 (fr) 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK60593D0 (da) 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
FR2742052B1 (fr) * 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
WO1997049698A1 (en) 1996-06-21 1997-12-31 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
DE69829317T2 (de) * 1997-12-25 2006-04-06 Meiji Seika Kaisha Ltd. Tetrahydrobenzindol-derivate
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
ATE412638T1 (de) 2001-02-16 2008-11-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
ES2201899B1 (es) * 2002-04-01 2005-06-01 Almirall Prodesfarma, S.A. Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
AU2006239302B2 (en) * 2005-04-26 2011-07-07 Hypnion, Inc. Benzisoxazole piperazine compounds and methods of use thereof

Also Published As

Publication number Publication date
CN101208314A (zh) 2008-06-25
DK1877390T3 (da) 2010-05-31
US20080214539A1 (en) 2008-09-04
CA2606471A1 (en) 2006-11-02
EP1877405A1 (en) 2008-01-16
CN101208314B (zh) 2010-12-08
CA2606473A1 (en) 2006-11-02
EP1877390A1 (en) 2008-01-16
DE602006013115D1 (de) 2010-05-06
PL1877390T3 (pl) 2010-08-31
US20090163514A1 (en) 2009-06-25
WO2006116614A1 (en) 2006-11-02
EP1877405B1 (en) 2010-03-03
DE602006012650D1 (de) 2010-04-15
PT1877390E (pt) 2010-05-31
JP2008539268A (ja) 2008-11-13
CA2606473C (en) 2013-08-13
ES2340066T3 (es) 2010-05-28
CA2606471C (en) 2014-02-11
JP2008539267A (ja) 2008-11-13
AU2006239302A1 (en) 2006-11-02
ATE459621T1 (de) 2010-03-15
ATE461925T1 (de) 2010-04-15
JP5049267B2 (ja) 2012-10-17
EP1877390B1 (en) 2010-03-24
US20070004752A1 (en) 2007-01-04
US8129410B2 (en) 2012-03-06
MX2007013352A (es) 2008-03-26
US8088778B2 (en) 2012-01-03
AU2006239302B2 (en) 2011-07-07
US7494998B2 (en) 2009-02-24
ES2341127T3 (es) 2010-06-15

Similar Documents

Publication Publication Date Title
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1114690T1 (el) Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
NO345046B1 (no) Oral doseringsform
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CY2017027I1 (el) Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
NO20081636L (no) FAP - inhibitorer
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
TW200732349A (en) Anti-OX40L antibodies and methods using same
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
CY1112950T1 (el) Νηματωδοκτονες συνθεσεις
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20081292L (no) Pentasykliske kinaseinhibitorer